Celecoxib instructions for administration

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753

Instructions for administration

Osteoarthritis

Rheumatoid arthritis

Ankylosing Spondylitis (AS)

Management of Acute Pain and Treatment of Primary Dysmenorrhea

Familial adenomatous polyposis (FAP)

Hepatic insufficiency

---

Osteoarthritis

For relief of the signs and symptoms of osteoarthritis the recommended oral dose is 200 mg per day administered as a single dose or as 100 mg twice per day. Return to top

Rheumatoid arthritis

For relief of the signs and symptoms of rheumatoid arthritis the recommended oral dose is 100 to 200 mg twice per day. Return to top

Ankylosing Spondylitis (AS)

For the management of the signs and symptoms of AS, the recommended dose of CELEBREX is 200 mg daily single (once per day) or divided (twice per day) doses. If no effect is observed after 6 weeks, a trial of 400 mg daily may be worthwhile. If no effect is observed after 6 weeks on 400 mg daily, a response is not likely and consideration should be given to alternate treatment options. Return to top

Management of Acute Pain and Treatment of Primary Dysmenorrhea

The recommended dose of CELEBREX is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed. Return to top

Familial adenomatous polyposis (FAP)

Usual medical care for FAP patients should be continued while on CELEBREX. To reduce the number of adenomatous colorectal polyps in patients with FAP, the recommended oral dose is 400 mg twice per day to be taken with food. Return to top

Hepatic insufficiency

The daily recommended dose of CELEBREX capsules in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by approximately 50%. The use of CELEBREX in patients with severe hepatic impairment is not recommended. Return to top

---

The content of this page is taken from the FDA package insert for this drug and should not be edited.